CD274 and breast carcinoma: It has been confirmed that CRGs could predict immunotherapy efficacy for breast cancer.[39] It may provide preliminary evidence for the potential of DLAT in predicting the efficacy of anti-PD-L1 immunotherapy for NSCLC.